Whitehawk Therapeutics (NASDAQ:WHWK) CEO David James Lennon Sells 26,858 Shares of Stock
by Scott Moore · The Cerbat GemWhitehawk Therapeutics, Inc. (NASDAQ:WHWK – Get Free Report) CEO David James Lennon sold 26,858 shares of the business’s stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $3.48, for a total transaction of $93,465.84. Following the completion of the sale, the chief executive officer owned 793,549 shares in the company, valued at $2,761,550.52. This represents a 3.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
David James Lennon also recently made the following trade(s):
- On Monday, March 2nd, David James Lennon sold 5,100 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.31, for a total transaction of $16,881.00.
Whitehawk Therapeutics Stock Performance
NASDAQ:WHWK opened at $3.51 on Friday. The company has a market capitalization of $165.66 million, a P/E ratio of 7.47 and a beta of 0.57. The firm has a 50-day moving average price of $3.28 and a two-hundred day moving average price of $2.66. Whitehawk Therapeutics, Inc. has a twelve month low of $1.39 and a twelve month high of $4.48.
Whitehawk Therapeutics (NASDAQ:WHWK – Get Free Report) last announced its quarterly earnings results on Thursday, March 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.21.
Wall Street Analyst Weigh In
WHWK has been the topic of a number of analyst reports. Oppenheimer initiated coverage on Whitehawk Therapeutics in a report on Thursday, February 5th. They set an “outperform” rating and a $6.00 target price on the stock. Wall Street Zen raised Whitehawk Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Whitehawk Therapeutics in a research report on Friday, March 27th. Finally, JonesTrading initiated coverage on Whitehawk Therapeutics in a research note on Monday, December 22nd. They set a “buy” rating and a $7.00 price objective on the stock. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $6.50.
Read Our Latest Stock Report on WHWK
Institutional Trading of Whitehawk Therapeutics
Institutional investors and hedge funds have recently made changes to their positions in the company. Quadrature Capital Ltd purchased a new position in shares of Whitehawk Therapeutics in the 4th quarter worth $28,000. ABG Innovation Capital Partners III GP Ltd purchased a new stake in Whitehawk Therapeutics during the third quarter valued at about $51,000. Geode Capital Management LLC increased its stake in Whitehawk Therapeutics by 11.4% during the fourth quarter. Geode Capital Management LLC now owns 425,440 shares of the company’s stock worth $1,030,000 after acquiring an additional 43,686 shares during the last quarter. Dimensional Fund Advisors LP acquired a new stake in Whitehawk Therapeutics during the third quarter worth about $84,000. Finally, Jane Street Group LLC raised its holdings in shares of Whitehawk Therapeutics by 177.3% in the 4th quarter. Jane Street Group LLC now owns 69,931 shares of the company’s stock worth $169,000 after purchasing an additional 44,716 shares during the period. 52.08% of the stock is currently owned by institutional investors and hedge funds.
About Whitehawk Therapeutics
Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.